TP53 and colorectal cancer: DAZAP2 inhibits the transactivation of a distinct set of p53 target genes in colorectal cancer cells, including pro-cell death genes upon DNA damage, thereby diminishing p53-induced cell death, presumably in response to repairable genome damage [53].